May 17th 2024
Check out this quiz on the NKF's KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for protein and energy intake!
10 Years of SGLT2 Inhibitors: A Decade of Redefining Cardiometabolic Care
March 29th 2023This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.
Daprodustat Receives FDA Approval for Anemia Caused by CKD on Dialysis
February 1st 2023Announced on February 1, the US Food and Drug Administration's approval of daprodustat (Jesduvroq) represents their first approval of an oral agent for the treatment of anemia caused by chronic kidney disease in people on dialysis.
Study Estimates Event-Free Survival with Combination SGLT2 and ACE/ARBs in People without Diabetes
November 23rd 2022Using data from a trio of trials, investigators provide insight into the potential benefits of combination therapy with SGLT2 inhibitors and RAAS inhibition on event-free survival among patients with chronic kidney disease without diabetes.
Finerenone Reduces Negative CV Outcomes in Type 2 Diabetes, Irrespective of Baseline Kidney Function
October 25th 2022An analysis of data from the FIDELITY program suggests use of finerenone reduced negative heart failure outcomes in people with diabetes and chronic kidney disease, regardless of baseline kidney function.
Managing CKD in the Face of a Growing Diabetes Epidemic, with Amy Mottl, MD
October 17th 2022In an interview at the 6th annual Cardio-Endo-Renal Collaborative from Physicians' Education Resource, Amy Mottl, MD, provides perspective on recent data from the CURE-CKD registry and problems facing nephrologists as they cope with an increasing prevalence of diabetes.
Study Details "Troubling" Rates of Chronic Kidney Disease in People with Diabetes
October 14th 2022An analysis of data from more than 640,000 people with diabetes recorded between 2015-2020 is providing new insight into what study investigators are calling "troubling" trends in the incidence of CKD in the face a growing diabetes epidemic.
Risk of Kidney Decline in T1D Heightened for People of African Caribbean Ethnicity
September 3rd 2022An analysis of data from more than 5500 people with type 1 diabetes and preserved kidney function at baseline suggests patients of African Caribbean ethnicity had a more than 50% greater risk of kidney function decline of 50% or greater than patients of other ethnic backgrounds.
Finerenone Reduces All-Cause Mortality, Sudden Cardiac Death in Type 2 Diabetes
August 29th 2022An analysis of the FIDELITY program from ESC Congress 2022 details an 11% reduction in risk of all-cause mortality and a 25% reduction in risk of sudden cardiac death among patients with type 2 diabetes and chronic kidney disease.